Stop TB Partnership

New TB vaccine candidate progresses to clinical trials

25 May 2011 - Zaragoza, Spain - Biopharmaceutical company Biofabri has announced that the MTBVAC01 vaccine candidate will start Phase I clinical trials in early 2012.

The vaccine was developed by the University of Zaragoza and is part of the international portfolio of the Tuberculosis Vaccine Initiative (TBVI).

The first batch of the vaccine is now available for toxicity studies. After the results of these studies have been assessed by the European Medicines Agency, the candidate will move to Phase I of clinical trials in humans. Phase I studies are conducted in small groups of healthy adults to check if the new vaccine can be given without any serious side effects or reaction and that it produces a good immune response. If the results are positive the vaccine candidate will move on to Phase II.